血清MFG-E8、FUC-HPT、Visfatin在溃疡性结肠炎中的表达意义

doi:10.3760/cma.j.cn441417-20241211-12022

摘要/Abstract

摘要：

目的　分析血清乳脂肪球表皮生长因子-8（milk fat globule epidermal growth factor 8，MFG-E8）、岩藻糖基化触珠蛋白（fucosylated haptoglobin，FUC-HPT）、内脂素（Visfatin）水平与溃疡性结肠炎（ulcerative colitis，UC）患者疾病活动指数及预后的关系。方法　选取2019年6月至2022年6月陕西省核工业二一五医院收治的UC患者170例为疾病组，另选取同期于陕西省核工业二一五医院体检的健康受试者170例为健康对照组。疾病组男87例，女83例，年龄（44.03±8.44）岁，体重指数（body mass index，BMI）（23.78±3.01）kg/m2。健康对照组男90例，女80例，年龄（45.17±7.59）岁，BMI（23.31±2.98）kg/m2。比较健康对照组、疾病组血清MFG-E8、FUC-HPT、Visfatin水平。疾病组根据UC活动度分为轻、中、重度活动组，比较轻、中、重度活动组血清MFG-E8、FUC-HPT、Visfatin水平。采用Pearson相关性分析法分析血清MFG-E8、FUC-HPT、Visfatin水平与Mayo评分的相关性。随访2年，记录疾病组患者预后情况，根据预后情况分为不良组、良好组，比较不良组、良好组一般资料及血清MFG-E8、FUC-HPT、Visfatin水平。用多因素logistic回归模型分析UC患者预后的影响因素。采用Pearson相关性分析法分析血清MFG-E8、FUC-HPT、Visfatin水平与预后（预后不良赋值为0，预后良好赋值为1）的相关性。采用独立样本t检验、Mann-Whitney U检验、方差分析、LSD-t检验进行统计学分析。结果　疾病组血清MFG-E8水平低于健康对照组（P<0.05），血清FUC-HPT、Visfatin水平高于健康对照组（均P<0.05）。中、重度活动组血清MFG-E8水平低于轻度活动组（均P<0.05），血清FUC-HPT、Visfatin水平高于轻度活动组（均P<0.05）；重度活动组血清MFG-E8水平低于中度活动组（P<0.05），血清FUC-HPT、Visfatin水平高于中度活动组（均P<0.05）。Pearson相关性分析显示，血清MFG-E8与Mayo评分负相关（r=-0.553，P<0.001），血清FUC-HPT、Visfatin水平与Mayo评分正相关（r=0.757、0.713，均P<0.001）。多因素logistic回归模型分析显示，正性负性情绪量表（Positive and Negative Affect Scale，PANAS）评分、肠外表现、基底浆细胞增加、FUC-HPT、Visfatin是UC患者预后不良的危险因素（均P<0.05），MFG-E8是预后的保护性因素（P<0.05）。Pearson相关性分析显示，血清MFG-E8与UC患者预后不良负相关（r=-0.345，P<0.001），血清FUC-HPT、Visfatin与UC患者预后不良正相关（r=0.607、0.616，均P<0.001）。结论　UC患者血清MFG-E8水平异常降低，血清FUC-HPT、Visfatin水平异常升高，与疾病活动度具有相关性，是UC患者预后的影响因素。

关键词: 溃疡性结肠炎, 乳脂肪球表皮生长因子-8, 岩藻糖基化触珠蛋白, 内脂素, 疾病活动指数, 预后

Abstract:

Objective　To analyze the relationship of the serum levels of milk fat globule epidermal growth factor 8 (MFG-E8), fucosylated haptoglobin (FUC-HPT), and visfatin with the disease activity index and prognosis in patients with ulcerative colitis (UC). Methods　A total of 170 patients with UC who were admitted to No. 215 Hospital of Shaanxi Nuclear Industry from June 2019 to June 2022 were selected as a disease group, while 170 healthy subjects who underwent physical examinations during the same period were selected as a healthy control group. There were 87 males and 83 females in the disease group; they were (44.03±8.44) years old; their body mass index (BMI) was (23.78±3.01) kg/m². There were 90 males and 80 females in the healthy control group; they were (45.17±7.59) years old; their BMI was (23.31±2.98) kg/m². The serum levels of MFG-E8, FUC-HPT, and visfatin were compared between the control group and the disease group. The disease group were further divided into mild, moderate, and severe activity groups based on their UC activity levels, and the serum levels of MFG-E8, FUC-HPT, and visfatin were compared between the 3 groups. The Pearson correlation analysis was used to examine the relationship of the serum levels of MFG-E8, FUC-HPT, and visfatin with the Mayo score. A two-year follow-up was conducted to record the patients' prognosis, and the disease group were categorized into poor and good prognosis groups based on their outcomes. The general data and serum levels of MFG-E8, FUC-HPT, and visfatin were compared between the poor and good prognosis groups. The multivariate logistic regression model was used to analyze the influencing factors of the patients' prognosis. The Pearson correlation analysis was again employed to investigate the correlation of the serum levels of MFG-E8, FUC-HPT, and visfatin with prognosis (with poor prognosis coded as 0 and good prognosis coded as 1). The independent sample t test, Mann-Whitney U test, analysis of variance, and LSD-t test were used for the statistical analysis. Results　Compared to the healthy control group, the disease group had a lower serum level of MFG-E8 (P<0.05) and higher levels of FUC-HPT and visfatin (both P<0.05). The serum levels of MFG-E8 in the moderate and severe activity groups were lower than that in the mild activity group, while the serum levels of FUC-HPT and visfatin were higher (all P<0.05). The serum level of MFG-E8 in the severe activity group was lower than that in the moderate activity group, while the levels of FUC-HPT and visfatin were higher (all P<0.05). The Pearson correlation analysis revealed that the serum MFG-E8 was negatively correlated with the Mayo score (r=-0.553; P<0.001), while the serum FUC-HPT and visfatin were positively correlated with the Mayo score (r=0.757 and 0.713; both P<0.001). The multivariate logistic regression analysis indicated that the score of Positive and Negative Affect Scale (PANAS), extraintestinal manifestations, increased basal plasmacytes, FUC-HPT, and visfatin were risk factors for poor prognosis in the patients (all P<0.05), whereas MFG-E8 was a protective factor (P<0.05). The Pearson correlation analysis showed that serum MFG-E8 was negatively correlated with poor prognosis (r=-0.345, P<0.001), and serum FUC-HPT and visfatin were positively correlated with poor prognosis (r=0.607 and 0.616; both P<0.001). Conclusion　The serum MFG-E8 level is abnormally reduced, and the serum FUC-HPT and visfatin levels are abnormally increased in patients with UC, which are correlated with the disease activity and are influencing factors for prognosis in patients with UC.

Key words: Ulcerative colitis, , Milk fat globule-epidermal growth factor-8, , Fucosylated haptoglobin, , Visfatin, , Disease activity index, , Prognosis

刘欣王惠萍雷蕾. 血清MFG-E8、FUC-HPT、Visfatin在溃疡性结肠炎中的表达意义 [J]. 国际医药卫生导报, 2025, 31(12): 2039-2045.

Liu Xin, Wang Huiping, Lei Lei.

Significance of serum MFG-E8, FUC-HPT, and visfatin expressions in ulcerative colitis [J]. International Medicine and Health Guidance News, 2025, 31(12): 2039-2045.

参考文献

[1]Buie MJ, Quan J, Windsor JW, et al. Global hospitalization trends for crohn's disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses[J]. Clin Gastroenterol Hepatol, 2023, 21(9):2211-2221. DOI: 10.1016/j.cgh.2022.06.030.

[2]Xu L, He B, Sun Y, et al. Incidence of inflammatory bowel disease in urban China: a nationwide population-based study[J]. Clin Gastroenterol Hepatol, 2023, 21(13): 3379-3386. DOI: 10.1016/j.cgh.2023.08.013.

[3]Spinelli A, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment [J]. J Crohns Colitis, 2022, 16(2):179-189. DOI: 10.1093/ecco-jcc/jjab177.

[4]徐明.理气清肠方加减联合美沙拉嗪治疗溃疡性结肠炎的效果[J].国际医药卫生导报, 2022, 28(3): 410-413. DOI: 10.3760/cma.j.issn.1007-1245.2022.03.027.

[5]Cui Q, Liu HC, Liu WM, et al. Milk fat globule epidermal growth factor 8 alleviates liver injury in severe acute pancreatitis by restoring autophagy flux and inhibiting ferroptosis in hepatocytes[J]. World J Gastroenterol, 2024, 30(7): 728-741. DOI: 10.3748/wjg.v30.i7.728.

[6]王迪,龙世群. Mac-2BP联合FUC-HPT对慢性肝炎患者病情严重程度的诊断价值[J].检验医学与临床, 2020, 17(6):784-787. DOI: 10.3969/j.issn.1672-9455.2020.06.019.

[7]Huang CL, Achudhan D, Liu PI, et al. Visfatin upregulates VEGF-C expression and lymphangiogenesis in esophageal cancer by activating MEK1/2-ERK and NF-κB signaling[J]. Aging (Albany NY), 2023, 15(11): 4774-4793. DOI: 10.18632/aging.204762.

[8]中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2018年•北京)[J].中国实用内科杂志, 2018, 38(9):796-813. DOI: 10.19538/j.nk2018090106.

[9]Gui X, Bazarova A, Del Amor R, et al. PICaSSO histologic remission index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system[J]. Gut, 2022, 71(5): 889-898. DOI: 10.1136/gutjnl-2021-326376.

[10]Caliendo G, D'Elia G, Makker J, et al. Biological, genetic and epigenetic markers in ulcerative colitis[J]. Adv Med Sci, 2023, 68(2): 386-395. DOI: 10.1016/j.advms. 2023.09.010.

[11]Gao X, Huang D, Yang LS, et al. Identification of gut microbiome and transcriptome changes in ulcerative colitis and pouchitis[J]. Scand J Gastroenterol, 2022, 57(8):942-952. DOI: 10.1080/00365521.2022.2047221.

[12]Li YY, Wang XJ, Su YL, et al. Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s[J]. Acta Pharmacol Sin, 2022, 43(6):1495-1507. DOI: 10.1038/s41401-021- 00781-7.

[13]李湘成,郭感恩,赵洁,等.血清PCT、NETs、MFG-E8、TLR 9与重症急性胰腺炎患者肠黏膜屏障功能的相关性分析及对预后的影响[J].现代生物医学进展,2023,23(5):963-968. DOI:10.13241/j.cnki.pmb.2023.05.033.

[14]Motooka K, Morishita K, Ito N, et al. Detection of fucosylated haptoglobin using the 10-7G antibody as a biomarker for evaluating endoscopic remission in ulcerative colitis[J]. World J Gastroenterol, 2021, 27(2): 162-175. DOI: 10.3748/wjg.v27.i2.162.

[15]Morshedzadeh N, Rahimlou M, Shahrokh S, et al. The effects of flaxseed supplementation on concentration of circulating adipokines in patients with ulcerative colitis[J]. Gastroenterol Hepatol Bed Bench, 2023, 16(1): 458-467. DOI: 10.22037/ghfbb.v16i1.2622.

[16]李霞,周宇,汤欣源. CDX2,miR-204-5p在溃疡性结肠炎患者黏膜组织中的表达及其与预后的关系[J].海南医学, 2022, 33(19): 2456-2459. DOI: 10.3969/j.issn. 1003-6350.2022.19.003.

[17]陶琴琴,赵亚静,杨晓明. microRNA-192表达量与溃疡性结肠炎患者炎性反应及预后的相关性[J].临床消化病杂志, 2024, 36(1): 16-21. DOI: 10.3870/lcxh.j.issn.1005- 541X.2024.01.004.

[18]Kozioł K, Owczarek D, Cibor D, et al. Serum level of lactadherin (MFGE8) in inflamatory bowel disease[J]. Folia Med Cracov, 2023, 63(3): 15-29. DOI: 10.24425/fmc.2023.147212.

[19]García-Alanis M, Toapanta-Yanchapaxi L, Reyes-Velásquez A, et al. The interrelation between anxiety and quality of life among patients with ulcerative colitis in remission[J]. Gastroenterol Hepatol, 2023, 46(10):747-753. DOI: 10.1016/j.gastrohep.2023.01.003.

[20]El-Zimaity H, Shaffer SR, Riddell RH, et al. Beyond neutrophils for predicting relapse and remission in ulcerative colitis[J]. J Crohns Colitis, 2023, 17(5):767-776. DOI: 10.1093/ecco-jcc/jjac178.